4 Stocks Dragging The Drugs Industry Downward

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 22 points (-0.1%) at 16,065 as of Monday, Dec. 2, 2013, 11:45 AM ET. The NYSE advances/declines ratio sits at 1,030 issues advancing vs. 1,883 declining with 116 unchanged.

The Drugs industry currently sits down 0.4% versus the S&P 500, which is unchanged.

TheStreet would like to highlight 4 stocks pushing the industry lower today:

4. Shire ( SHPG) is one of the companies pushing the Drugs industry lower today. As of noon trading, Shire is down $2.81 (-2.1%) to $133.00 on light volume. Thus far, 162,198 shares of Shire exchanged hands as compared to its average daily volume of 454,700 shares. The stock has ranged in price between $132.65-$133.56 after having opened the day at $133.10 as compared to the previous trading day's close of $135.81.

Shire plc, a biopharmaceutical company, researches, develops, manufactures, sells, and distributes pharmaceutical products. It operates in three segments: Specialty Pharmaceuticals (SP), Human Genetic Therapies (HGT), and Regenerative Medicine (RM). Shire has a market cap of $25.5 billion and is part of the health care sector. The company has a P/E ratio of 36.9, above the S&P 500 P/E ratio of 17.7. Shares are up 47.5% year to date as of the close of trading on Friday. Currently there are 10 analysts that rate Shire a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Shire as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, increase in net income, good cash flow from operations and solid stock price performance. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Shire Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

3. As of noon trading, Sanofi ( SNY) is down $0.79 (-1.5%) to $52.04 on heavy volume. Thus far, 1.2 million shares of Sanofi exchanged hands as compared to its average daily volume of 1.4 million shares. The stock has ranged in price between $52.02-$52.34 after having opened the day at $52.18 as compared to the previous trading day's close of $52.83.

Sanofi researches, develops, manufactures, and markets healthcare products worldwide. The company operates through Pharmaceuticals, Human Vaccines, and Animal Health segments. Sanofi has a market cap of $140.2 billion and is part of the health care sector. The company has a P/E ratio of 28.3, above the S&P 500 P/E ratio of 17.7. Shares are up 11.1% year to date as of the close of trading on Friday. Currently there are 2 analysts that rate Sanofi a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Sanofi as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Sanofi Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Alexion Pharmaceuticals ( ALXN) is down $1.78 (-1.4%) to $122.72 on light volume. Thus far, 203,891 shares of Alexion Pharmaceuticals exchanged hands as compared to its average daily volume of 981,300 shares. The stock has ranged in price between $122.22-$124.80 after having opened the day at $124.58 as compared to the previous trading day's close of $124.50.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of life-transforming therapeutic products. Alexion Pharmaceuticals has a market cap of $23.8 billion and is part of the health care sector. The company has a P/E ratio of 68.5, above the S&P 500 P/E ratio of 17.7. Shares are up 29.3% year to date as of the close of trading on Friday. Currently there are 14 analysts that rate Alexion Pharmaceuticals a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Alexion Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, growth in earnings per share and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Alexion Pharmaceuticals Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Gilead ( GILD) is down $0.49 (-0.7%) to $74.32 on average volume. Thus far, 4.5 million shares of Gilead exchanged hands as compared to its average daily volume of 8.6 million shares. The stock has ranged in price between $73.61-$74.97 after having opened the day at $74.84 as compared to the previous trading day's close of $74.81.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases in North America, Europe, and Asia. Gilead has a market cap of $114.4 billion and is part of the health care sector. The company has a P/E ratio of 41.0, above the S&P 500 P/E ratio of 17.7. Shares are up 103.7% year to date as of the close of trading on Friday. Currently there are 15 analysts that rate Gilead a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, reasonable valuation levels, expanding profit margins and good cash flow from operations. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Gilead Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 4 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).
null